GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Maccura Biotechnology Co Ltd (SZSE:300463) » Definitions » Beneish M-Score

Maccura Biotechnology Co (SZSE:300463) Beneish M-Score : -2.89 (As of Apr. 17, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Maccura Biotechnology Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.89 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Maccura Biotechnology Co's Beneish M-Score or its related term are showing as below:

SZSE:300463' s Beneish M-Score Range Over the Past 10 Years
Min: -3.28   Med: -2.36   Max: -1.09
Current: -2.89

During the past 13 years, the highest Beneish M-Score of Maccura Biotechnology Co was -1.09. The lowest was -3.28. And the median was -2.36.


Maccura Biotechnology Co Beneish M-Score Historical Data

The historical data trend for Maccura Biotechnology Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maccura Biotechnology Co Beneish M-Score Chart

Maccura Biotechnology Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.16 -2.43 -3.15 -2.23 -2.97

Maccura Biotechnology Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.85 -2.97 -2.82 -2.82 -2.89

Competitive Comparison of Maccura Biotechnology Co's Beneish M-Score

For the Diagnostics & Research subindustry, Maccura Biotechnology Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Maccura Biotechnology Co's Beneish M-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Maccura Biotechnology Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Maccura Biotechnology Co's Beneish M-Score falls into.


;
;

Maccura Biotechnology Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Maccura Biotechnology Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9591+0.528 * 0.9845+0.404 * 1.0012+0.892 * 0.9079+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1823+4.679 * -0.055092-0.327 * 0.9795
=-2.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Total Receivables was ¥1,620 Mil.
Revenue was 668.704 + 662.545 + 616.367 + 780.689 = ¥2,728 Mil.
Gross Profit was 384.926 + 375.108 + 353.872 + 438.574 = ¥1,552 Mil.
Total Current Assets was ¥3,902 Mil.
Total Assets was ¥8,206 Mil.
Property, Plant and Equipment(Net PPE) was ¥3,324 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥349 Mil.
Total Current Liabilities was ¥1,239 Mil.
Long-Term Debt & Capital Lease Obligation was ¥151 Mil.
Net Income was 79.647 + 81.283 + 120.442 + 43.941 = ¥325 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was 280.319 + 207.796 + 4.884 + 284.39 = ¥777 Mil.
Total Receivables was ¥1,861 Mil.
Revenue was 734.357 + 704.323 + 676.4 + 890.121 = ¥3,005 Mil.
Gross Profit was 424.857 + 362.794 + 374.227 + 521.674 = ¥1,684 Mil.
Total Current Assets was ¥4,475 Mil.
Total Assets was ¥8,233 Mil.
Property, Plant and Equipment(Net PPE) was ¥2,777 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥325 Mil.
Total Current Liabilities was ¥1,206 Mil.
Long-Term Debt & Capital Lease Obligation was ¥217 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1620.231 / 2728.305) / (1860.728 / 3005.201)
=0.59386 / 0.619169
=0.9591

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1683.552 / 3005.201) / (1552.48 / 2728.305)
=0.560213 / 0.569027
=0.9845

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (3902 + 3324.348) / 8205.887) / (1 - (4474.641 + 2776.517) / 8232.699)
=0.11937 / 0.119225
=1.0012

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2728.305 / 3005.201
=0.9079

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 2776.517)) / (0 / (0 + 3324.348))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(348.937 / 2728.305) / (325.081 / 3005.201)
=0.127895 / 0.108173
=1.1823

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((150.987 + 1238.842) / 8205.887) / ((217.138 + 1206.465) / 8232.699)
=0.16937 / 0.172921
=0.9795

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(325.313 - 0 - 777.389) / 8205.887
=-0.055092

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Maccura Biotechnology Co has a M-score of -2.89 suggests that the company is unlikely to be a manipulator.


Maccura Biotechnology Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Maccura Biotechnology Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Maccura Biotechnology Co Business Description

Traded in Other Exchanges
N/A
Address
Number 8, 2nd Anhe Road, Hi-tech Zone, Chengdu, CHN, 611731
Maccura Biotechnology Co Ltd is a China-based in-vitro diagnostic (IVD) integration company engaged in the research and development, production and sales of IVD products. It is also engaged in the sales of foreign brands of in vitro diagnostic products as an agent. The company's developed product and technology development platforms cover clinical biochemistry, chemiluminescent immunoassay, rapid diagnosis, thrombosis, hemostasis, and molecular diagnosis.
Executives
Guo Lei Director
Wang Deng Ming Directors, executives
Wang Lin Supervisors
Wu Ming Jian Directors, executives
Shi Wei Directors, executives
Yang Hui Supervisors
Zhou Yue Guo Executives
Wang Zhen Executives
Yu Ping Executives
Zou Yuan Supervisors
Xu Sheng Guo Directors, executives
Liu Qi Lin Directors, executives
Chu Jian Jun Executives
Tang Yong Director
Xu Jin Song Executives

Maccura Biotechnology Co Headlines

No Headlines